Literature DB >> 16527885

Influence of sample type and storage conditions on soluble CD40 ligand assessment.

Michael Weber1, Birgitt Rabenau, Michael Stanisch, Albrecht Elsaesser, Vesselin Mitrovic, Christopher Heeschen, Christian Hamm.   

Abstract

BACKGROUND: Several studies have consistently shown that soluble CD40 ligand (sCD40L) concentrations are increased in patients with acute coronary syndromes and can serve as a biomarker for risk stratification. However, few data are available on preanalytic conditions that impact sCD40L values. Thus, the aim of our prospective study was to evaluate the impact of sampling techniques and storage conditions on sCD40L concentrations.
METHODS: We included a total of 30 patients with no, stable, or unstable coronary heart disease. Blood samples were collected in gel-filled tubes without additives, in EDTA-filled tubes, and in citrate-filled tubes and were kept at various storage conditions.
RESULTS: Median (interquartile range) sCD40L values at baseline were higher in serum samples [5.29 (3.89-6.33) microg/L] than in either EDTA plasma [0.78 (0.39-1.12) microg/L; P <0.001] or citrate plasma [0.37 (0.22-0.51) microg/L; P <0.001]. Serum values increased with delayed processing [7.94 (5.97-9.62) microg/L after 1.5 h (P <0.001) vs baseline; 10.55 (7.58-11.55) microg/L after 3 h (P <0.001) vs baseline]. However, after centrifugation, sCD40L values remained stable for all 3 sample types.
CONCLUSION: Plasma, but not serum, samples are appropriate for sCD40L measurements. In general, preanalytic conditions are critical in the assessment of sCD40L concentrations and thus should be carefully considered for future studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16527885     DOI: 10.1373/clinchem.2005.062083

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

Review 1.  Designing and managing a flexible and dynamic biorepository system: a 15-year perspective from the CPCRA, ESPRIT, and INSIGHT clinical trial networks.

Authors:  Katherine H Hullsiek; Michelle George; Shawn K Brown
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

Review 2.  CD40/CD40L system and vascular disease.

Authors:  F Santilli; S Basili; P Ferroni; G Davì
Journal:  Intern Emerg Med       Date:  2007-11-28       Impact factor: 3.397

3.  Effect of anticoagulants on multiplexed measurement of cytokine/chemokines in healthy subjects.

Authors:  Angélique Biancotto; Xingmin Feng; Marc Langweiler; Neal S Young; J Philip McCoy
Journal:  Cytokine       Date:  2012-06-15       Impact factor: 3.861

4.  Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16.

Authors:  Benjamin A Olenchock; Stephen D Wiviott; Sabina A Murphy; Christopher P Cannon; Nader Rifai; Eugene Braunwald; David A Morrow
Journal:  J Thromb Thrombolysis       Date:  2007-10-05       Impact factor: 2.300

5.  Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.

Authors:  David A Morrow; Marc S Sabatine; Marie-Luise Brennan; James A de Lemos; Sabina A Murphy; Christian T Ruff; Nader Rifai; Christopher P Cannon; Stanley L Hazen
Journal:  Eur Heart J       Date:  2008-03-12       Impact factor: 29.983

6.  Platelet-derived CD154: ultrastructural localization and clinical correlation in organ transplantation.

Authors:  A H Charafeddine; E J Kim; D M Maynard; H Yi; T A Weaver; M Gunay-Aygun; M Russell; W A Gahl; A D Kirk
Journal:  Am J Transplant       Date:  2012-09-04       Impact factor: 8.086

7.  Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis.

Authors:  Leonardo Lorente; María M Martín; Nerea Varo; Juan María Borreguero-León; Jordi Solé-Violán; José Blanquer; Lorenzo Labarta; César Díaz; Alejandro Jiménez; Eduardo Pastor; Felipe Belmonte; Josune Orbe; José A Rodríguez; Eduardo Gómez-Melini; José M Ferrer-Agüero; José Ferreres; María C Llimiñana; José A Páramo
Journal:  Crit Care       Date:  2011-03-15       Impact factor: 9.097

8.  New frontiers for platelet CD154.

Authors:  Antoine Dewitte; Annabelle Tanga; Julien Villeneuve; Sébastien Lepreux; Alexandre Ouattara; Alexis Desmoulière; Christian Combe; Jean Ripoche
Journal:  Exp Hematol Oncol       Date:  2015-03-01

9.  Evidence and Cost Effectiveness Requirements for Recommending New Biomarkers.

Authors:  Paul Collinson
Journal:  EJIFCC       Date:  2015-08-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.